Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

FGF19 (Fibroblast growth factor 19)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

FGF19 expression	Ovarian Cancer	FGF19 expression	Ovarian Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	ABSK011 Sensitive: C2 – Inclusion Criteria ABSK011 Sensitive : C2	ABSK011 Sensitive: C2 – Inclusion Criteria ABSK011 Sensitive : C2
FGF19 amplification + ER positive	HER2 Negative Breast Cancer	FGF19 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF19 elevation	Hepatocellular Cancer	FGF19 elevation	Hepatocellular Cancer	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
FGF19-L	Hepatocellular Cancer	FGF19-L	Hepatocellular Cancer	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3	lenvatinib Sensitive: C3 – Early Trials lenvatinib Sensitive : C3
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3
FGF19 negative	Hepatocellular Cancer	FGF19 negative	Hepatocellular Cancer	BLU-554 Resistant: C3 – Early Trials BLU-554 Resistant : C3	BLU-554 Resistant: C3 – Early Trials BLU-554 Resistant : C3
FGF19 overexpression	Hepatocellular Cancer	FGF19 overexpression	Hepatocellular Cancer	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3	BLU-554 Sensitive: C3 – Early Trials BLU-554 Sensitive : C3
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	H3B-6527 Sensitive: C3 – Early Trials H3B-6527 Sensitive : C3	H3B-6527 Sensitive: C3 – Early Trials H3B-6527 Sensitive : C3
FGF19 mutation	Urothelial Cancer	FGF19 mutation	Urothelial Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
FGF19 positive	Hepatocellular Cancer	FGF19 positive	Hepatocellular Cancer	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3	sugemalimab + BLU-554 Sensitive: C3 – Early Trials sugemalimab + BLU-554 Sensitive : C3
FGF19 expression	Hepatocellular Cancer	FGF19 expression	Hepatocellular Cancer	lenvatinib Sensitive: D – Preclinical lenvatinib Sensitive : D	lenvatinib Sensitive: D – Preclinical lenvatinib Sensitive : D